THE EVOLVING APPROACH TO DRUG VALUE ASSESSMENT IN GLOBAL MARKETS
Author(s)
Aris Angelis, PhD, London School of Economics, London, UK; Jennifer Cain Birkmose, MBA, MPH, BS, Roche, Basel, Switzerland; David Rees, BA, MBA, Health Strategies Group, Yardley, USA; Michael Schlander, MD, PhD, MBA, Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany; Sanjay Shah, BS, MBA, Visionary Ventures, LLC, Morganville, USA; Andreas Wildi, MD, MLaw, Walderwyss Attorneys at Law, Zurich, Switzerland
Presentation Documents
David Rees, Principal of Health Strategies Group, will lead a panel of industry market access marketers in a discussion of the evolving approach to drug assessment in global markets. This interactive session will address how the global access stakeholder’s approach to assessment of drug value is changing, the disparity in value assessments, and how the emerging model is different from the current mode.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Topic
Economic Evaluation, Health Technology Assessment